<?xml version="1.0" encoding="UTF-8"?>

<ValueSet xmlns="http://hl7.org/fhir">
  <id value="shr-oncology-OncotypeDxDCISRiskScoreInterpretationVS"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml">
<p><b>SHR OncotypeDxDCISRiskScoreInterpretationVS ValueSet</b></p>
<p>Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score</p>
</div>
  </text>
  <url value="http://standardhealthrecord.org/shr/oncology/vs/OncotypeDxDCISRiskScoreInterpretationVS"/>
  <identifier>
    <system value="http://standardhealthrecord.org"/>
    <value value="shr.oncology.OncotypeDxDCISRiskScoreInterpretationVS"/>
  </identifier>
  <version value="0.1.0"/>
  <name value="OncotypeDxDCISRiskScoreInterpretationVS"/>
  <title value="SHR OncotypeDxDCISRiskScoreInterpretationVS ValueSet"/>
  <status value="draft"/>
  <date value="2018-08-21T00:00:00-04:00"/>
  <publisher value="The MITRE Corporation: Standard Health Record Collaborative"/>
  <contact>
    <telecom>
      <system value="url"/>
      <value value="http://standardhealthrecord.org"/>
    </telecom>
  </contact>
  <description value="Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score"/>
  <compose>
    <include>
      <system value="http://standardhealthrecord.org/shr/oncology/cs/OncotypeDxDCISRiskScoreInterpretationCS"/>
      <concept>
        <code value="low_risk"/>
        <display value="Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects."/>
      </concept>
      <concept>
        <code value="intermediate_risk"/>
        <display value="Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It&#x2019;s unclear whether the benefits of chemotherapy outweigh the risks of side effects."/>
      </concept>
      <concept>
        <code value="high_risk"/>
        <display value="Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects."/>
      </concept>
    </include>
  </compose>
</ValueSet>